Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry

This publication has 24 references indexed in Scilit:

• The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well‐differentiated and dedifferentiated liposarcoma oncogenesis. An analysis of 104 tumors
  Genes, Chromosomes and Cancer, 2011
• Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?
  Laboratory Investigation, 2010
• Molecular Testing for Lipomatous Tumors: Critical Analysis and Test Recommendations Based on the Analysis of 405 Extremity-based Tumors
  American Journal of Surgical Pathology, 2010
• Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours
  Journal of Clinical Pathology, 2009
• Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas
  Clinical Cancer Research, 2009
• Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms
  Laboratory Investigation, 2008
• HMGA2 is the partner of MDM2 in well‐differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon
  International Journal of Cancer, 2008
• The Regulation of INK4/ARF in Cancer and Aging
  Cell, 2006
• Soft-Tissue Sarcomas in Adults
  New England Journal of Medicine, 2005
• p16INK4a Is a Useful Marker for the Diagnosis of Adenocarcinoma of the Cervix Uteri and Its Precursors
  American Journal of Surgical Pathology, 2003